Development of immunotherapy for glioblastoma using EGFRvIII specific CAR transduced immune cells
| Project/Area Number |
16K10767
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中村 光利 奈良県立医科大学, 医学部附属病院, 研究員 (00305715)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 悪性神経膠芽腫 / キメラ受容体 / ナチュラルキラー細胞 / EGFRvIII / アポトーシス / Glioblastoma / Immunotherapy / Chimeric antigen / Natural killer cell / T cell / 脳腫瘍学 / 腫瘍免疫 |
|---|
| Outline of Final Research Achievements |
Among glioblastoma cells, 40% of tumor cells express EGFRvIII antigen. Using tumor growth inhibition assay, we have proved EGFRvIII tumor antigen specific chimeric antigen receptor(CAR)-natural killer(NK)cells(KHYG-1) have an ability to inhibit the tumor growth of U87 tumor cell line which expressed EGFRvIII antigen. Also, using apoptosis detection assay, we have proved that EGFRvIII-CAR-NK-KHYG-1 induced tumor antigen specific apoptosis against U87. We reported those results on ANTICANCER RESEARCH 38:5049-5056(2018).
|
| Academic Significance and Societal Importance of the Research Achievements |
悪性神経膠芽腫に対する治療の3本柱は、手術、化学療法、放射線治療であるが、それでも難治性の腫瘍であるため、治療が非常に有効な可能性のある免疫療法が必要である。我々は、免疫細胞であるナチュラルキラー細胞株に、遺伝子導入を用いて、腫瘍抗原特異的なキメラ受容体を導入し、腫瘍増殖抑制効果と、腫瘍抗原特異的なアポトーシスが誘導されることを証明した。この基礎研究により、将来的に臨床応用の可能性も考えられ、学術的にも社会的にも意義があると考えられる。今後は、さらに動物実験などでのキメラ受容体発現ナチュラルキラー細胞の抗腫瘍効果を評価していきたいと考えている。
|
Report
(4 results)
Research Products
(4 results)
-
[Journal Article] Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.2018
Author(s)
Murakami T, Nakazawa T(equally contribution), Natsume A, Nishimura F, Nakamura M, Matsuda R, Omoto K, Tanaka Y, Shida Y, Park YS, Motoyama Y, Nakagawa I, Yamada S, Tamura K, Takeshima Y, Takamura Y,
-
Journal Title
Anticancer Res
Volume: 38
Issue: 9
Pages: 5049-5056
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Presentation] Establishment of an efficient ex-vivo expansion method for highly purified human natural killer cells and evaluation of their antitumor activity on glioblastoma2019
Author(s)
Nakazawa T, Tanaka Y, Shida Y, Nakamura M, Nishimura F, Matsuda R, Murakami T, Nakagawa I, Motoyama Y, Tsujimura T, Nakase H.
Organizer
Keystone Symposia: Innate and Non-Classical Immune Cells in Cancer Immunotherapy
Related Report
Int'l Joint Research
-
-
